University of Bordeaux

About: University of Bordeaux is a education organization based out in Bordeaux, France. It is known for research contribution in the topics: Population & Laser. The organization has 28811 authors who have published 55536 publications receiving 1619635 citations. The organization is also known as: UB.

Is TENS purely a placebo effect? A controlled study on chronic low back pain *

Abstract: Although high-frequency low-intensity transcutaneous electric nerve stimulation (TENS) has been extensively used to relieve low back pain, experimental studies of its effectiveness have yielded contradictory findings mainly due to methodological problems in pain evaluation and placebo control. In the present study, separate visual analog scales (VAS) were used to measure the sensory-discriminative and motivational-affective components of low back pain. Forty-two subjects were randomly assigned to 1 of 3 groups: TENS, placebo-TENS, and no treatment (control). In order to measure the short-term effect of TENS, VAS pain ratings were taken before and after each treatment session. Also, to measure long-term effects, patients rated their pain at home every 2 h throughout a 3-day period before and 1 week, 3 months and 6 months after the treatment sessions. In comparing the pain evaluations made immediately before and after each treatment session, TENS and placebo-TENS significantly reduced both the intensity and unpleasantness of chronic low back pain. TENS was significantly more efficient than placebo-TENS in reducing pain intensity but not pain unpleasantness. TENS also produced a significant additive effect over repetitive treatment sessions for pain intensity and relative pain unpleasantness. This additive effect was not found for placebo-TENS. When evaluated at home, pain intensity was significantly reduced more by TENS than placebo-TENS 1 week after the end of treatment, but not 3 months and 6 months later. At home evaluation of pain unpleasantness in the TENS group was never different from the placebo-TENS group.(ABSTRACT TRUNCATED AT 250 WORDS)

Thermoluminescence dates for the Neanderthal burial site at Kebara in Israel

Abstract: The origins of modern man are a subject of controversy among palaeoanthropologists concerned with human evolution1–3 Particularly heavily debated is the dating of hominid remains uncovered in southwestern Asia, because middle palaeolithic sites have provided skeletal remains classified as representing Neanderthals (Homo sapiens neanderthalensis at Tabun, Amud, Kebara and Shanidar caves) and proto-Cro-Magnons (Homo sapiens sapiens at Skhul and Qafzeh caves) This situation differs considerably from that of Western Europe, where only Neanderthal remains are known from archaeological deposits of this period, or that of the African continent, where no Neanderthal remains have so far been found Two opposing hypotheses have been offered to explain the relations between Neanderthals and the earliest modern Homo sapiens: first that modern Homo sapiens appeared very early in the Mediterranean Levant and coexisted with a population of Neanderthals who had arrived at a later date; and second that modern humans developed from the local Neanderthal population in southwestern Asia Recent excavations at the Kebara cave yielded Neanderthal burial in a well-documented stratigraphic and cultural Mousterian sequence4,5 We now report that ther-moluminescence dates from 38 specimens of burnt flint recovered from 4 m of Kebara deposits range from about 60,000 to 48,000 years before present (BP), indicating that Neanderthals were present in the Levant in the latter part of the middle Palaeolithic

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Abstract: OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). DESIGN: Observational multicentre cohorts. METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification. RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.